Immunomedics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Morris Plains NJ United States (1982)
Status: Acquired by Gilead Sciences (2020)

Organization Overview

First Clinical Trial
1997
NCT00003337
First Marketed Drug
2020
sacituzumab govitecan (Trodelvy)
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Immunomedics, Inc. | IMMUNOMEDICS INC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma, Follicular (Phase 2)

Aggression (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 2)

Carcinoma, Neuroendocrine (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Carcinoma, Transitional Cell (Phase 3)

Colonic Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 2)

Endometrial Neoplasms (Phase 2)

Esophageal Neoplasms (Phase 2)

Glioblastoma (Phase 2)

Graft vs Host Disease (Phase 1)

Head and Neck Neoplasms (Phase 2)

Leukemia (Phase 2)

Leukemia, B-Cell (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 1)

Leukemia, Myeloid (Phase 1)

Leukemia, Prolymphocytic (Phase 2)

Liver Failure (Phase 1)

Lung Neoplasms (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 2)

Lupus Erythematosus, Discoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Lupus Nephritis (Phase 2)

Lupus Vasculitis, Central Nervous System (Phase 2)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 1)

Lymphoma, Follicular (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 1)

Lymphoma, Non-Hodgkin (Phase 3)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 1)

Neoplasm Metastasis (Phase 3)

Neoplasms (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Nephritis (Phase 2)

Pancreatic Neoplasms (Phase 3)

Plasmacytoma (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 1)

Prostatic Neoplasms (Phase 2)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombocytopenic, Idiopathic (Phase 2)

Rectal Neoplasms (Phase 2)

Recurrence (Phase 2)

Small Cell Lung Carcinoma (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Thyroid Diseases (Phase 2)

Thyroid Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Vasculitis (Phase 2)

Vasculitis, Central Nervous System (Phase 2)

Waldenstrom Macroglobulinemia (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 55
  • # of Trial APIs: 29